Adding Ianalumab to Ibrutinib Induces Deep Remissions and Enables Therapy Discontinuation in Chronic Lymphocytic Leukemia
A Phase Ib study reveals that adding the anti-BAFF-R antibody ianalumab to ibrutinib therapy achieves high rates of undetectable measurable residual disease (uMRD), allowing over 40% of CLL patients to successfully discontinue long-term treatment while maintaining remission.
